Immuron Limited has partnered with InvestorHub to enhance communication with investors. The company has launched an interactive investor hub for sharing content. CEO Steven Lydeamore anticipates FDA approval for IMM-529 and Travelan clinical trial results this year. IMM-529 is being developed as an adjunctive therapy for recurrent Clostridioides difficile infection. The platform technology uses bovine antibodies to target infectious diseases. Travelan is a tabletized preparation to prevent travelers’ diarrhea. Immuron also has an exclusive distribution agreement for ProIBS, a medical device for Irritable Bowel Syndrome symptoms. Visit their website for more information.

Read more at GlobeNewswire: Immuron partners with InvestorHub